These findings provide a basis for developing drugs that can differentially target the α1 and α2 subunits of AMPK to treat diseases such as obesity and osteoporosis that are associated with mutations in specific AMPK subunits. This evidence concerns the gene PRKAA2 and obesity due to melanocortin 4 receptor deficiency.